Stockreport

Halozyme down 16% premarket on research showing no incremental treatment benefit for PEGPH20 in pancreatic cancer [Seeking Alpha]

Halozyme Therapeutics, Inc.  (HALO) 
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: halozyme.com/investors/default.aspx
PDF Halozyme down 16% premarket on research showing no incremental treatment benefit for PEGPH20 in pancreatic cancerHalozyme Therapeutics (NASDAQ:HALO) slumps16% premarket [Read more]